Kathryn A Grako

US Patent:

8163269, Apr 24, 2012

Filed:

Apr 4, 2005

Appl. No.:

11/098891

Inventors:

Kenneth W. Carpenter - San Diego CA, US
William G. Turnell - San Diego CA, US
Kristin M. DeFife - San Diego CA, US
Kathryn A. Grako - San Diego CA, US

International Classification:

A61M 36/14
A61K 51/00

US Classification:

424 169, 424 111, 424 165, 424 91, 514 11

Abstract:

The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.

US Patent:

20020049176, Apr 25, 2002

Filed:

Feb 27, 2001

Appl. No.:

09/795651

Inventors:

Christen Anderson - Encinitas CA, US
William Clevenger - Oceanside CA, US
K. Becker - San Diego CA, US
Kathryn Grako - San Diego CA, US

International Classification:

A61K048/00

US Classification:

514/044000

Abstract:

Compositions and methods are provided for the treatment of diseases associated with altered mitochondrial function, and in particular, for type 2 diabetes mellitus. Administration of an agent that increases mitochondrial mass, including promotion of mitochondrial biogenesis by induction of a PGC gene (e.g., PGC-1) and/or a nuclear regulatory factor gene (e.g., NRF-1), is also disclosed. Screening assays for agents that regulate such genes involved in mitochondrial biogenesis, and for genes and gene products that are regulated by such genes involved in mitochondrial biogenesis, are also provided.

US Patent:

20060013855, Jan 19, 2006

Filed:

Jun 7, 2005

Appl. No.:

11/147994

Inventors:

Kenneth Carpenter - San Diego CA, US
William Turnell - San Diego CA, US
Kristin DeFife - San Diego CA, US
Kathryn Grako - San Diego CA, US

Assignee:

MediVas, LLC - San Diego CA

International Classification:

A61F 2/00

US Classification:

424423000

Abstract:

The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.

US Patent:

20080020015, Jan 24, 2008

Filed:

Apr 26, 2007

Appl. No.:

11/796267

Inventors:

Kenneth Carpenter - La Jolla CA, US
William Turnell - San Diego CA, US
Kristin DeFife - San Diego CA, US
Kathryn Grako - San Diego CA, US
Ramaz Katsarava - Tbilisi GA, US

Assignee:

MediVas, LLC - San Diego CA

International Classification:

A61K 35/12
A61F 13/00
A61K 9/00
A61P 17/02

US Classification:

424426000, 424422000, 424445000, 424093700

Abstract:

The present invention provides wound dressings, optionally surgically implantable, containing biodegradable, polymers and hydrogels having allogenic or autologous precursor cells, such as stem cells and progenitor cells dispersed within. Alternatively, the wound dressings can have conditioned medium obtained from the precursor cells dispersed within. The wound dressings promote tissue restoration processes at a site of application or implantation. Additional bioactive agents can also be dispersed within the polymer/hydrogel matrix, which can be formulated to biodegrade at a controlled rate by adjusting the composition. Methods are also provided for using such biodegradable wound dressings as a delivery device or carrier for the precursor cells, conditioned medium and bioactive agents, or as coatings on implantable medical devices, to promote tissue restoration at a lesion site.

US Patent:

20080288057, Nov 20, 2008

Filed:

Apr 4, 2006

Appl. No.:

11/885791

Inventors:

Kenneth W. Carpenter - San Diego CA, US
William G. Turnell - San Diego CA, US
Kristin M. Defife - San Diego CA, US
Kathryn A. Grako - San Diego CA, US

International Classification:

A61F 2/82
A61F 2/24

US Classification:

623 142, 623 242, 424426

Abstract:

The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.

US Patent:

20110137406, Jun 9, 2011

Filed:

Oct 26, 2010

Appl. No.:

12/912440

Inventors:

Kenneth W. Carpenter - San Diego CA, US
William G. Turnell - San Diego CA, US
Kristin M. DeFife - San Diego CA, US
Kathryn A. Grako - San Diego CA, US

Assignee:

MediVas, LLC - San Diego CA

International Classification:

A61F 2/82

US Classification:

623 142

Abstract:

The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.